{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:13:50Z","timestamp":1790140430013,"version":"4.0.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.soncn.2022.151276","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T08:01:13Z","timestamp":1651132873000},"page":"151276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacological Prevention and Management of Skeletal-Related Events and Bone Loss in Individuals with Cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Jiyeon Joy","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.soncn.2022.151276_bib0001","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.soncn.2022.151276_bib0002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/j.1875-9114.2011.01092.x","article-title":"Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor","volume":"32","author":"Iranikhah","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.soncn.2022.151276_bib0003","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"10.1016\/j.soncn.2022.151276_bib0004","first-page":"12","article-title":"Impact of cancer therapy on the reproductive axis","volume":"59","author":"Muller","year":"2003","journal-title":"Horm Res"},{"issue":"3","key":"10.1016\/j.soncn.2022.151276_bib0005","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.soncn.2022.151276_bib0006","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soncn.2022.151276_bib0007","unstructured":"Fresenius Kabi USA LLC. Zoledronic acid (Zometa): Package insert. 2018."},{"key":"10.1016\/j.soncn.2022.151276_bib0008","unstructured":"Amgen Inc. Denosumab (Xgeva): Package insert. 2020."},{"key":"10.1016\/j.soncn.2022.151276_bib0009","unstructured":"Novartis Pharmaceuticals Corporation. Zoledronic acid (Reclast): Package insert. 2020."},{"key":"10.1016\/j.soncn.2022.151276_bib0010","unstructured":"Amgen Inc. Denosumab (Prolia): Package insert. 2021."},{"key":"10.1016\/j.soncn.2022.151276_bib0011","unstructured":"Areva Pharmaceuticals Inc. Pamidronate disodium: Package insert. 2015."},{"issue":"11","key":"10.1016\/j.soncn.2022.151276_bib0012","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","author":"Mirrakhimov","year":"2015","journal-title":"N Am J Med Sci"},{"issue":"Suppl 3","key":"10.1016\/j.soncn.2022.151276_bib0013","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.soncn.2022.151276_bib0014","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO Clinical Practice Guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.soncn.2022.151276_bib0015","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.3747\/co.2008.174","article-title":"Cancer treatment-related bone loss: a review and synthesis of the literature","volume":"15","author":"Khan","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1016\/j.soncn.2022.151276_bib0016","doi-asserted-by":"crossref","unstructured":"D'Oronzo S, Stucci S, Tucci M, Silvestris F. Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev. 2015;41(9):798-808. doi:10.1016\/j.ctrv.2015.09.003","DOI":"10.1016\/j.ctrv.2015.09.003"},{"issue":"10","key":"10.1016\/j.soncn.2022.151276_bib0017","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.soncn.2022.151276_bib0018","series-title":"Assessment of osteoporosis at the primary health-care level","author":"Kanis","year":"2021"},{"issue":"26","key":"10.1016\/j.soncn.2022.151276_bib0019","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1200\/JCO.2007.15.4997","article-title":"Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer","volume":"26","author":"Saarto","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.soncn.2022.151276_bib0020","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.soncn.2022.151276_bib0021","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.soncn.2022.151276_bib0022","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soncn.2022.151276_bib0023","series-title":"Zoledronic acid","year":"2022"},{"key":"10.1016\/j.soncn.2022.151276_bib0024","series-title":"Pamidronate","year":"2022"},{"key":"10.1016\/j.soncn.2022.151276_bib0025","series-title":"Denosumab","year":"2022"},{"issue":"13","key":"10.1016\/j.soncn.2022.151276_bib0026","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.soncn.2022.151276_bib0027","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.soncn.2022.151276_bib0028","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol"},{"issue":"34","key":"10.1016\/j.soncn.2022.151276_bib0029","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soncn.2022.151276_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pract"},{"issue":"25","key":"10.1016\/j.soncn.2022.151276_bib0031","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.soncn.2022.151276_bib0032","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JOP.17.00013","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology Clinical Practice Guideline update summary","volume":"14","author":"Anderson","year":"2018","journal-title":"J Oncol Pract"},{"issue":"2","key":"10.1016\/j.soncn.2022.151276_bib0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JOP.2011.000486","article-title":"Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project","volume":"9","author":"Edwards","year":"2013","journal-title":"J Oncol Pract"},{"issue":"9","key":"10.1016\/j.soncn.2022.151276_bib0034","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.soncn.2022.151276_bib0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.soncn.2022.151276_bib0036","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4419-1050-9_2","article-title":"Activation of gammadelta T cells by bisphosphonates","volume":"658","author":"Thompson","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"35","key":"10.1016\/j.soncn.2022.151276_bib0037","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.soncn.2022.151276_bib0038","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.soncn.2022.151276_bib0039","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: The OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.soncn.2022.151276_bib0040","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.soncn.2022.151276_bib0041","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.soncn.2022.151276_bib0042","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00044011-200626060-00002","article-title":"Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial","volume":"26","author":"Pecherstorfer","year":"2006","journal-title":"Clin Drug Investig"},{"issue":"10001","key":"10.1016\/j.soncn.2022.151276_bib0043","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.soncn.2022.151276_bib0044","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.soncn.2022.151276_bib0045","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","article-title":"Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment","volume":"95","author":"Hershman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.soncn.2022.151276_bib0046","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2022.151276_bib0047","unstructured":"National Comprehensive Cancer Network. Breast cancer version 1.2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed December 10, 2021."},{"issue":"35","key":"10.1016\/j.soncn.2022.151276_bib0048","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soncn.2022.151276_bib0049","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9992","key":"10.1016\/j.soncn.2022.151276_bib0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.soncn.2022.151276_bib0051","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soncn.2022.151276_bib0052","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.soncn.2022.151276_bib0053","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"issue":"15","key":"10.1016\/j.soncn.2022.151276_bib0054","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO Endorsement of a Cancer Care Ontario Guideline","volume":"38","author":"Saylor","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soncn.2022.151276_bib0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.soncn.2022.151276_bib0056","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.soncn.2022.151276_bib0057","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"9768","key":"10.1016\/j.soncn.2022.151276_bib0058","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"9810","key":"10.1016\/j.soncn.2022.151276_bib0059","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.soncn.2022.151276_bib0060","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.juro.2009.08.048","article-title":"Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer","volume":"182","author":"Smith","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.soncn.2022.151276_bib0061","unstructured":"National Comprehensive Cancer Network. Multiple Myeloma version 4.2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed December 14, 2021."},{"key":"10.1016\/j.soncn.2022.151276_bib0062","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"10.1016\/j.soncn.2022.151276_bib0063","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9757","key":"10.1016\/j.soncn.2022.151276_bib0064","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.soncn.2022.151276_bib0065","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.soncn.2022.151276_bib0066","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soncn.2022.151276_bib0067","unstructured":"U.S. Department of Health and Human Services. Physical activity guidelines for Americans. 2nd ed. Available at: https:\/\/health.gov\/sites\/default\/files\/2019-09\/Physical_Activity_Guidelines_2nd_edition.pdf. Accessed January 5, 2022."},{"key":"10.1016\/j.soncn.2022.151276_bib0068","unstructured":"U.S. Department of Agriculture and U.S. Department of Health and Human Services. 2020-2025 Dietary guidelines for Americans. 9th ed. Available at: https:\/\/www.dietaryguidelines.gov\/sites\/default\/files\/2020-12\/Dietary_Guidelines_for_Americans_2020-2025.pdf. Accessed January 5, 2022."},{"issue":"24","key":"10.1016\/j.soncn.2022.151276_bib0069","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2018.7498","article-title":"Screening for osteoporosis to prevent fractures: US Preventive Services Task Force Recommendation Statement","volume":"319","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.soncn.2022.151276_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.soncn.2022.151276_bib0071","unstructured":"Amgen Inc. Romosozumab-aqqg (Evenity): Package insert. 2020."},{"issue":"15","key":"10.1016\/j.soncn.2022.151276_bib0072","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208122000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208122000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:39:09Z","timestamp":1760081949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208122000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0749208122000298"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2022.151276","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Prevention and Management of Skeletal-Related Events and Bone Loss in Individuals with Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2022.151276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151276"}}